MX2009006530A - Formas de estado solido de ilaprazol racemico. - Google Patents

Formas de estado solido de ilaprazol racemico.

Info

Publication number
MX2009006530A
MX2009006530A MX2009006530A MX2009006530A MX2009006530A MX 2009006530 A MX2009006530 A MX 2009006530A MX 2009006530 A MX2009006530 A MX 2009006530A MX 2009006530 A MX2009006530 A MX 2009006530A MX 2009006530 A MX2009006530 A MX 2009006530A
Authority
MX
Mexico
Prior art keywords
solid state
racemic ilaprazole
state forms
ilaprazole
methyl
Prior art date
Application number
MX2009006530A
Other languages
English (en)
Inventor
John M Brackett
David T Jonaitis
Wei Lai
Stephan D Parent
Jih Hua Liu
Jinyu Shen
Original Assignee
Il Yang Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharmaceutical Company filed Critical Il Yang Pharmaceutical Company
Publication of MX2009006530A publication Critical patent/MX2009006530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a formas cristalinas de ilaprazol racémico, 2[[(4-metoxi-3-metil-2-piridinil)metil]sulfinil]5-(1H-pi rrol-1-il)-1 H-bencimi5 dazol. La invención se refiere también a una composición farmacéutica para inhibir la secreción de ácido gástrico, que comprende una forma cristalina de ilaprazol de acuerdo con la invención, en una cantidad efectiva para inhibir la secreción de ácido gástrico, y un portador aceptable para uso farmacéutico. La invención provee también métodos para tratar diversos trastornos gastrointestinales (GI) relacionados con el ácido.
MX2009006530A 2006-12-29 2007-12-28 Formas de estado solido de ilaprazol racemico. MX2009006530A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31
PCT/US2007/089127 WO2008083333A1 (en) 2006-12-29 2007-12-28 Solid state forms of racemic ilaprazole

Publications (1)

Publication Number Publication Date
MX2009006530A true MX2009006530A (es) 2009-08-18

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009006530A MX2009006530A (es) 2006-12-29 2007-12-28 Formas de estado solido de ilaprazol racemico.
MX2009006529A MX2009006529A (es) 2006-12-29 2007-12-28 Formas cristalinas de ilaprazol solvatado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009006529A MX2009006529A (es) 2006-12-29 2007-12-28 Formas cristalinas de ilaprazol solvatado.

Country Status (19)

Country Link
US (4) US7989632B2 (es)
EP (2) EP2102191B1 (es)
JP (2) JP5315254B2 (es)
KR (3) KR20090086121A (es)
CN (2) CN101687848B (es)
AU (2) AU2007341992B2 (es)
CA (2) CA2674347C (es)
DK (1) DK2102192T3 (es)
ES (1) ES2398846T3 (es)
HK (2) HK1140483A1 (es)
IL (2) IL199234A (es)
MX (2) MX2009006530A (es)
MY (2) MY146462A (es)
NO (2) NO20092398L (es)
NZ (2) NZ577509A (es)
PL (1) PL2102192T3 (es)
PT (1) PT2102192E (es)
RU (2) RU2466129C2 (es)
WO (2) WO2008083341A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JP2005533755A (ja) 2002-03-27 2005-11-10 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール多形及びその調製方法
WO2006099810A1 (en) 2005-03-25 2006-09-28 Livzon Pharmaceutical Group Inc. Substituted sulfoxide compounds, methods for preparing the same and use thereof
EP1879577A1 (en) * 2005-05-04 2008-01-23 AstraZeneca AB Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
NO342530B1 (no) 2018-06-11
US8592599B2 (en) 2013-11-26
HK1140484A1 (en) 2010-10-15
HK1140483A1 (en) 2010-10-15
WO2008083341A1 (en) 2008-07-10
EP2102191B1 (en) 2012-11-21
MX2009006529A (es) 2009-08-18
CA2674347C (en) 2013-08-06
DK2102192T3 (da) 2013-03-04
RU2464270C2 (ru) 2012-10-20
US20110082174A1 (en) 2011-04-07
NO20092398L (no) 2009-09-28
MY146462A (en) 2012-08-15
NO20092464L (no) 2009-09-28
CN101687849A (zh) 2010-03-31
PT2102192E (pt) 2013-01-23
KR20090086615A (ko) 2009-08-13
JP5315253B2 (ja) 2013-10-16
JP2010514806A (ja) 2010-05-06
AU2007341992A1 (en) 2008-07-10
JP5315254B2 (ja) 2013-10-16
IL199242A (en) 2013-10-31
IL199234A (en) 2013-07-31
AU2007341984A1 (en) 2008-07-10
EP2102191A1 (en) 2009-09-23
US20110046184A1 (en) 2011-02-24
KR101052387B1 (ko) 2011-07-28
EP2102192B1 (en) 2012-11-14
US20080200516A1 (en) 2008-08-21
RU2009122241A (ru) 2011-02-10
CA2674347A1 (en) 2008-07-10
CN101687848A (zh) 2010-03-31
AU2007341984B2 (en) 2012-07-05
US7999110B2 (en) 2011-08-16
JP2010514807A (ja) 2010-05-06
RU2466129C2 (ru) 2012-11-10
CA2674358A1 (en) 2008-07-10
US8592600B2 (en) 2013-11-26
RU2009122242A (ru) 2011-02-10
EP2102192A1 (en) 2009-09-23
CN101687848B (zh) 2013-05-15
WO2008083333A1 (en) 2008-07-10
AU2007341992B2 (en) 2012-07-05
MY145936A (en) 2012-05-31
ES2398846T3 (es) 2013-03-22
NZ577509A (en) 2012-01-12
KR20090086121A (ko) 2009-08-10
NZ577129A (en) 2012-02-24
US20080200517A1 (en) 2008-08-21
CA2674358C (en) 2013-10-08
KR20110091594A (ko) 2011-08-11
PL2102192T3 (pl) 2013-04-30
CN101687849B (zh) 2013-05-29
US7989632B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
MX2009006530A (es) Formas de estado solido de ilaprazol racemico.
MY145696A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-menthyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester-methanesulfonate and its use as a medicament
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007134678A3 (de) Triazolderivate ii
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
IL187236A0 (en) Compositions and methods for inhibiting gastric acid secretion
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
MX2009000080A (es) Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
PH12014500079A1 (en) 6-substituted phenoxychroman carboxylic acid derivatives
WO2008040774A3 (en) Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2007138468A3 (en) Processes for the preparation of lansoprazole
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
TW200800993A (en) Organic compounds
WO2010117756A3 (en) Substituted benzimidazole pharmaceutical formulations
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
WO2006067599A3 (en) Stable oral benzimidazole compositions and process of preparation thereof
WO2008084067A3 (en) Pharmaceutically active dihydrobenzofurane-substituted benzimidazole derivatives
WO2008017466A8 (en) Pharmaceutically active tetrahydroisoquinoline-substituted benzimidazole derivatives
WO2009117160A3 (en) Compound and method for treatment of gastroesophageal reflux

Legal Events

Date Code Title Description
FG Grant or registration